Pulmonary Arterial Hypertension Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pulmonary
Arterial Hypertension – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Pulmonary Arterial Hypertension – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also
reviews of key players involved in therapeutic development for Pulmonary
Arterial Hypertension and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase
I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1,
11, 14, 14, 1, 38, 5 and 1 respectively. Similarly, the Universities
portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules,
respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Pulmonary Arterial Hypertension (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Pulmonary
  Arterial Hypertension (Cardiovascular) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Pulmonary
  Arterial Hypertension (Cardiovascular) therapeutics and enlists all
  their major and minor projects.
• The pipeline guide evaluates Pulmonary Arterial Hypertension
  (Cardiovascular) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy:

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Pulmonary Arterial Hypertension (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and
  focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Aadi Bioscience Inc
• Acceleron Pharma Inc
• Actelion Pharmaceuticals Ltd
• Aerogen Ltd
• AI Therapeutics
• AVEO Pharmaceuticals Inc
• Bayer AG
• Bial – Portela & Ca SA
• Biogen Inc
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Co
• Camurus AB
• Capricor Therapeutics Inc
• Celsion Corp
• Celtaxsys Inc
• Chiesi Farmaceutici SpA
• Chugai Pharmaceutical Co Ltd
• Complexa Inc
• Denovo Biopharma LLC
• Eli Lilly and Co
• Gilead Sciences Inc
• GlaxoSmithKline Plc
• Gossamer Bio Inc
• Insmed Inc
• Insys Therapeutics Inc
• Japan Tobacco Inc
• Liquidia Technologies Inc
• Martin Pharmaceuticals Inc
• Merck & Co Inc
• Mezzion Pharma Co Ltd
• Nippon Shinyaku Co Ltd
• Nissan Chemical Corp
• Northern Therapeutics Inc
• Novartis AG
• Peloton Therapeutics Inc
• PhaseBio Pharmaceuticals Inc
• Pulmokine Inc
• Q BioMed Inc
• Radikal Therapeutics Inc
• Reata Pharmaceuticals Inc
• Relief Therapeutics Holding AG
• Respira Therapeutics Inc
• Resverlogix Corp
• Reviva Pharmaceuticals Inc
• SteadyMed Therapeutics Inc
• Suda Pharmaceuticals Ltd
• Takeda Pharmaceutical Co Ltd
• Toray Industries Inc
• United Therapeutics Corp
• Vicore Pharma AB
• Vivus Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/szgfgr/pulmonary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs